ID: ALA5274126

Max Phase: Preclinical

Molecular Formula: C12H19N3O11P2

Molecular Weight: 443.24

Representations

Canonical SMILES:  CO/N=c1\ccn([C@]23C[C@H]2[C@@H](COP(=O)(O)OP(=O)(O)O)[C@@H](O)[C@H]3O)c(=O)[nH]1

Standard InChI:  InChI=1S/C12H19N3O11P2/c1-24-14-8-2-3-15(11(18)13-8)12-4-7(12)6(9(16)10(12)17)5-25-28(22,23)26-27(19,20)21/h2-3,6-7,9-10,16-17H,4-5H2,1H3,(H,22,23)(H,13,14,18)(H2,19,20,21)/t6-,7+,9-,10-,12-/m1/s1

Standard InChI Key:  PGNXKCIKBOSKRG-WBAPNQQASA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 443.24

Molecular Weight (Monoisotopic): 443.0495

AlogP: -2.07

#Rotatable Bonds: 7

Polar Surface Area: 213.13

Molecular Species: ACID

HBA: 10

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 14

HBD (Lipinski): 6

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 1.78

CX Basic pKa:

CX LogP: -2.44

CX LogD: -7.50

Aromatic Rings: 1

Heavy Atoms: 28

QED Weighted: 0.20

Np Likeness Score: 1.13

References

1. Jacobson KA, Salmaso V, Suresh RR, Tosh DK..  (2021)  Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.,  12  (11.0): [PMID:34825182] [10.1039/D1MD00167A]

Source

Source(1):

• Scientific Literature